These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33063216)

  • 1. Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice.
    Marchionatti A; Woodhall M; Waters PJ; Sato DK
    Neurol Sci; 2021 Jan; 42(1):73-80. PubMed ID: 33063216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination.
    Ayroza Galvão Ribeiro Gomes AB; Kulsvehagen L; Lipps P; Cagol A; Cerdá-Fuertes N; Neziraj T; Flammer J; Lerner J; Lecourt AC; de Oliveira S Siebenborn N; Cortese R; Schaedelin S; Andreoli Schoeps V; de Moura Brasil Matos A; Trombini Mendes N; Dos Reis Pereira C; Ribeiro Monteiro ML; Dos Apóstolos-Pereira SL; Schindler P; Chien C; Schwake C; Schneider R; Pakeerathan T; Aktas O; Fischer U; Mehling M; Derfuss T; Kappos L; Ayzenberg I; Ringelstein M; Paul F; Callegaro D; Kuhle J; Papadopoulou A; Granziera C; Pröbstel AK
    JAMA Neurol; 2023 Sep; 80(9):989-995. PubMed ID: 37548987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis].
    Eliseeva DD; Vasiliev AV; Shabalina AA; Simaniv TO; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):13-23. PubMed ID: 32844625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays.
    Tzartos JS; Karagiorgou K; Tzanetakos D; Breza M; Evangelopoulos ME; Pelidou SH; Bakirtzis C; Nikolaidis I; Koutsis G; Notas K; Chroni E; Markakis I; Grigoriadis NC; Anagnostouli M; Orologas A; Parisis D; Karapanayiotides T; Papadimitriou D; Kostadima V; Elloul J; Xidakis I; Maris T; Zisimopoulou P; Tzartos S; Kilidireas C
    J Neurol Sci; 2020 Mar; 410():116673. PubMed ID: 31954354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement.
    Sugimoto K; Mori M; Liu J; Tanaka S; Kaneko K; Oji S; Takahashi T; Uzawa A; Uchida T; Masuda H; Ohtani R; Nomura K; Hiwasa T; Kuwabara S
    J Neuroimmunol; 2019 Nov; 336():577021. PubMed ID: 31473520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study.
    Weber J; Bernsdorff N; Robinson T; Endres D; Rauer S; Berger B
    J Neurol Sci; 2021 Feb; 421():117289. PubMed ID: 33360733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Mariotto S; Gajofatto A; Batzu L; Delogu R; Sechi G; Leoni S; Pirastru MI; Bonetti B; Zanoni M; Alberti D; Schanda K; Monaco S; Reindl M; Ferrari S
    Neurology; 2019 Nov; 93(20):e1867-e1872. PubMed ID: 31645473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?
    Di Pauli F; Berger T
    Front Immunol; 2018; 9():2753. PubMed ID: 30555462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of MOG-IgG in Clinical Samples by Live Cell-Based Assays: Performance of Immunofluorescence Microscopy and Flow Cytometry.
    Marchionatti A; Hansel G; Avila GU; Sato DK
    Front Immunol; 2021; 12():642272. PubMed ID: 34025652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
    Banwell B; Bennett JL; Marignier R; Kim HJ; Brilot F; Flanagan EP; Ramanathan S; Waters P; Tenembaum S; Graves JS; Chitnis T; Brandt AU; Hemingway C; Neuteboom R; Pandit L; Reindl M; Saiz A; Sato DK; Rostasy K; Paul F; Pittock SJ; Fujihara K; Palace J
    Lancet Neurol; 2023 Mar; 22(3):268-282. PubMed ID: 36706773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases.
    Kim Y; Hyun JW; Woodhall MR; Oh YM; Lee JE; Jung JY; Kim SY; Lee MY; Kim SH; Kim W; Irani SR; Waters P; Choi K; Kim HJ
    Mult Scler Relat Disord; 2020 May; 40():101939. PubMed ID: 31978673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases.
    Spadaro M; Meinl E
    Methods Mol Biol; 2016; 1304():99-104. PubMed ID: 25814289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes.
    Ferilli MAN; Valeriani M; Papi C; Papetti L; Ruscitto C; Figà Talamanca L; Ursitti F; Moavero R; Vigevano F; Iorio R
    Mult Scler Relat Disord; 2021 May; 50():102837. PubMed ID: 33636614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.